Medinice has published a roadmap of five key projects. According to the adopted work schedule, the closest to commercialization is PacePress – an innovative compression dressing used in cardiac electrostimulation. The start of its certification process is scheduled for the end of 2023, the company said.
“Medinice S.A. published a roadmap of five key projects. The closest to commercialization is PacePress. The certification process is scheduled to start by the end of 2023. Further certifications are scheduled for the third quarter of 2024 – for MiniMax and CoolCryo. Currently, both products are in the preclinical phase and will enter the clinical phase in the fourth quarter of this year. At the end of 2023, the preclinical phase for EP Bioptom and AtriClamp will begin, and the certification stage will fall on 2025.” – we read in the message.
The diversified portfolio of the Company currently includes several projects. The current pipeline consists of five key products:
- PacePress – automatic tourniquet, the task of which is to minimize complications after procedures (e.g. implantation of a pacemaker or ICD)
- MiniMax – the world’s first minimally invasive cardiac ablation electrode with 3D mapping that does not require X-rays, making it a safer option for the patient and staff
- CoolCryo – a cryoapplicator for performing surgical cryoablation (the temperature reached is minus 160-180 degrees, competitors are in the range of minus 40-120 degrees)
- AtriClamp – an innovative left atrial appendage closure technology used to reduce the risk of ischemic stroke and other complications in patients with atrial fibrillation
- EP Bioptom – electrophysiological diagnostic electrode used for endomyocardial biopsy, performed e.g. after heart transplant procedures, listed in the information.
“We are in the midst of an intense and very busy period. Our team is working hard to meet the expectations of the market. We are doing our best to have five medical devices certified by 2025. To achieve this, we focus on two flagship projects a year, without forgetting the others, of course. The research and development process has its rhythm and that’s why we adapted the new roadmap to it. Let us remember that in the Medtech industry, commercialization may take place earlier, for example at the stage of clinical trials or certification,” said Arkadiusz Dorynek, Vice-President of Medinice, quoted in the release.
Medinice is a Polish company with a global reach, which is a platform for solutions used in cardiology. The company develops its own projects and projects obtained from scientists from Poland and abroad. The company debuted on the main market of the Warsaw Stock Exchange in 2020.